NervGen Pharma Corp. (NGEN)
NASDAQ: NGEN · Real-Time Price · USD
1.620
+0.020 (1.25%)
Jul 31, 2026, 4:00 PM EDT - Market closed
NervGen Pharma Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, NervGen Pharma stock has a consensus rating of "Buy" and an average price target of $10.6. The average 1-year stock price forecast is 554.32% higher than the current stock price, while the lowest is $5.03 (+210.49%) and the highest is $18 (+1,011.11%).
Price Target: $10.6 (+554.32%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for NervGen Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 3 | 2 | 3 | 4 |
| Buy | 2 | 3 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 7 | 6 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $18 → $15 | Buy | Reiterates | $18 → $15 | +825.93% | Jul 14, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $10 | Buy | Initiates | $10 | +517.28% | Jul 13, 2026 |
| TD Cowen | TD Cowen | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 11, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Reiterates $6 | Buy | Reiterates | $6 | +270.37% | May 21, 2026 |
| Lucid Capital | Lucid Capital | Buy Initiates $18 | Buy | Initiates | $18 | +1,011.11% | Apr 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.27
from -0.44
EPS Next Year
-0.32
from -0.27
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CAD.